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• ATL cells over-express Wnt5a, which enhances osteoclastogenesis and may contribute to the osteolytic bone lesions and hypercalcemia.
ABSTRACT:
Adult T-cell leukemia/lymphoma (ATLL) is etiologically linked to infection with the human T-cell leukemia/lymphoma virus type 1 (HTLV-I). ATLL is classified into four distinct clinical diseases: acute, lymphoma, chronic and smoldering. Acute ATL is the most aggressive form, representing 60% of cases and has a 4 year survival of less than 5%. A frequent complication and cause of death in acute ATL patients is the presence of lytic bone lesions and hypercalcemia. We analyzed the Wnt/β-catenin pathway due to its common role in cancer and bone remodeling. Our study demonstrated that ATL cells do not express high levels of β -catenin, but displayed high levels of LEF-1/TCF genes along with elevated levels of β -catenin (LEF-1/TCF-target genes) responsive genes. By profiling Wnt gene expression we discovered that ATL patient leukemia cells shifted expression towards the non-canonical Wnt pathway. Interestingly, ATL cells overexpressed the osteolytic-associated genes, Wnt5a, PTHLH and RANKL. We further show that Wnt5a secreted by ATL cells favors osteoclast differentiation and expression of RANK. Our results suggest that Wnt5a is a major contributing factor to the increase in osteolytic bone lesions and hypercalcemia found in ATL patients. Anti-Wnt5a therapy may prevent or reduce osteolytic lesions found in ATL patients and improve therapy outcome.
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INTRODUCTION:
Wnt signaling has a role in embryonic development, adult homeostasis, and disease, and acts through the canonical and non-canonical beta-catenin (β-catenin) pathways. Wnt signaling is required for the self-renewal of normal and neoplastic stem cells in the hematopoietic system, and activation of β -catenin may contribute to acquisition of the self-renewal capacity of leukemia stem cells 1;2 . The non-canonical
Wnt pathway results in changes in cell polarity, motility, migration, and axon guidance.
The non-canonical Wnt pathway also antagonizes the canonical Wnt pathway, which is β -catenin dependent and plays an important role in cellular proliferation, fate, and differentiation. Activation of the β -catenin pathway has been demonstrated in several cancer types and is involved in the pathogenesis of leukemia/lymphomas, such as acute myelogenous leukemia (AML), chronic lymphocytic leukemia (CLL), mantle cell lymphoma (MCL), and a sub-set of T-cell non-Hodgkins lymphomas (NHL) [3] [4] [5] . In addition, primary patient samples from acute lymphoblastic leukemia (ALL), AML, and multiple myeloma (MM), have abnormal methylation of Wnt antagonists [6] [7] [8] . In the absence of Wnt signaling, β -catenin is phosphorylated and degraded by a complex consisting of glycogen synthase kinase 3 (GSK3-β), adenomatous polyposis coli (APC), casein kinase 1 (CK1), and axin 9 . Wnt signaling can relieve β -catenin degradation, through activation of dishevelled, which blocks phosphorylation by GSK3-β.
Wnt signaling is also recognized as a key developmental pathway involved in osteoblast differentiation. De-regulation of, or mutations in, low-density lipoprotein receptor-related protein-5 (LRP5), LRP6, Frizzled-9, Wnt10b, and Wnt5a have been shown to disrupt bone regulation 10 . Activation of the non-canonical Wnt pathway by Wnt5a also leads to enhanced osteoclastogenesis by increasing the expression of RANK, which is impaired in mouse knock-outs of Wnt5a or its receptor, Ror2 11 .
We have previously shown that over-expression of the HTLV-I post transcriptional regulator p30 leads to an increase in phosphorylated GSK3-β on Ser9 12 .
Phosphorylation of Ser9 on GSK3-β by AKT results in GSK3-β inhibition, and subsequent β -catenin activation 13 . However, the effects of p30 and Tax We also found that leukemic cells from ATL patients express high levels of the pro-osteoclastic genes, Wnt5a, RANKL and PTHrP. Importantly, Wnt5a secreted by ATL cells was able to induce osteoclast differentiation in vitro, which could be prevented by addition of Wnt5a antibodies in the culture media. Overall our data supports a model in which osteolytic lesions in ATL patients are by-products of an altered Wnt/β-catenin pathway and over-expression of Wnt5a. 
IL-2 (50 U/ml) was added to the HTLV-I RNA extraction, PCR, and Real-time Quantitative PCR: RNA was extracted using TRIzol (Invitrogen) and treated with DNaseI (Roche Applied Science, Indianapolis, IN).
Total RNA was reverse transcribed using the RNA-to-cDNA synthesis kit (Applied Biosystems, Carlsbad, CA). cDNA was used in PCR reactions, with GAPDH amplification in non-saturating conditions used as a control. PCR products were visualized by electrophoresis using 1.8% agarose gels stained with ethidium bromide.
Quantitative real-time PCR was performed using RT 2 Real-time SYBR Green PCR master mix (SABiosciences, Valencia, CA) on the StepOnePlus Real-time PCR System (Applied Biosystems), with GAPDH expression serving as an internal control. Fold change is calculated as the ratio of normalized expression of the target gene divided by the normalized expression of the control sample. Primers are provided as supplemental data (Supplemental Table 1 ). Cell extracts were lysed in 1x Passive Lysis Buffer (Promega, Madison, WI) and analyzed using the Luciferase Reporter Assay System (Promega), according to the manufacturer's instructions. Luciferase assays were performed at least twice from independent experiments, and results were normalized to Renilla luciferase or protein concentration, as indicated in the figure legends. Cell Cycle and Flow Cytometry: 1185 cells were grown with 20% serum and 50 U/ml IL-2 or removed of serum, IL-2, and treated with 0.1µM hydroxyurea (Sigma-Aldrich) for 48 hours. RNA was extracted for real-time PCR or lysates were stained with propidium iodine (Invitrogen) for cell cycle analysis using the LSRII flow cytometer.
Co-culture System and Alkaline Phosphatase Assay (ALP): C2C12 cells were seeded onto 0.4µM Transwell plates one day prior to induction. MT1-pTRIPZ or MT1-DKK-1
Tet-inducible cell lines were added to the Transwells inserts. When indicated, Wnt5a antibody (R&D Systems, Minneapolis, MN) or Rabbit IgG control antibody (Santa-Cruz), 50 ng/ml rWnt3a (R&D Systems), 30 ng/ml rRANKL (PeproTech, Rocky Hill, NJ) or 100 ng/ml rBMP-2 (R&D Biosystems) was added to the Transwells. After 48 hours, RNA was extracted from the C2C12 cells and used for real-time quantitative PCR analysis.
For ALP activity, C2C12 cells were cultured for 5 days, as stated above. Cells were For personal use only. on July 15, 2017. by guest www.bloodjournal.org From lysed in assay buffer and enzyme activity was determined after incubation at 30 C using the Alkaline Phosphatase Activity Colorimetric Assay Kit (BioVision, Milpitas, CA.).
Measurements were taken at 405nm using an Anthos 2010 microplate reader (Biochrom, Holliston, MA). Enzyme activity was normalized to total protein concentration (Bio-Rad, Hercules, CA). The MT1-DKK-1 cell line was established by cloning DKK-1 into the pTRIPZ inducible, lentiviral vector (Thermo Scientific, Waltham, MA.). High titer virus was produced in 293T cells by co-transfection with the VSV-G and pDLN packaging system and used to infect MT1 cells. Stable cell lines were obtained by puromycin selection. DKK-1 expression was induced with 2 µg/ml doxycycline.
RESULTS:
The Wnt/β-catenin pathway is constitutively activated in HTLV-I transformed cells.
We first performed western blot analysis on total cellular extracts derived from HTLV-I cell lines and examined the level of Figure 1E and Suppl.). However, Wnt5a
was strongly expressed in all HTLV-I cell lines ( Figure 1F ) and ATL lines (Suppl.). Wnt5a
is a key non-canonical Wnt ligand and has roles in β Several pathways are known to target GSK3-β for degradation, including growth factors that stimulate the mitogen-activated protein kinase (MAPK), phosphoinositide-3-kinase (PI3K)/AKT, or Wnt pathways. Given the fact that the PI3K/AKT pathway is active in HTLV cells, we hypothesized that PI3K/AKT may be inhibiting GSK3-β 1 9 . We found that inhibition of PI3K kinase activity with LY294002, led to a loss of p-GSK3β Figure 2D ). Similar to Tax, we found p30 could also induce β -catenin transcriptional activity, albeit at a lower level ( Figure 2D ). In addition, we found that the Figure 3E ). We also found that in general, LEF-1/TCF-1 were over-expressed and higher than TCF-4 gene expression, except in the case of two patients (ATL5 and ATL7)
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( Figure 3F ). In two different ATL patients the pattern was the opposite, and TCF-4 was expressed at higher levels than LEF-1/TCF-1 (ATL6 and ATL15).
We then analyzed the underlying mechanism by which LEF-1 and TCF expression was increased in ATL patient samples compared to HTLV-I cell lines. We next analyzed ATL patient samples for expression of the Wnt pathway. Figure 4A and 4C) . A common feature to both HTLV-I cell lines and ATL samples was the high levels of Wnt5a expression ( Figure 4B ). To further confirm this data and get more accurate results we performed real time RT-PCR for Wnt5a. Our data showed over-expression of Wnt5a in approximately 75% of acute ATL samples ( Figure   4D ). In addition to Wnt5a's role in Wnt signaling, Wnt5a has also been shown to enhance osteoclastogenesis 11 . This is signficant, since hypercalcemia and osteolytic bone lesions are frequently reported in patients with acute ATL 21 . This suggests that Wnt5a may play a role in bone resorption and the subsequent hypercalcemia in acute ATL patients. We therefore, compared the levels of PTHLH (PTHrP, parathyroid hormone-like hormone)and RANKL (TNFSF11, tumor necrosis factor (ligand)
superfamily, member 11), which have been previously reported to be elevated in ATL patients and are involved in hypercalcemia 15;22 . We found these genes were also overexpressed in about 85% of ATL patients ( Figure 4E and 4F). These results suggest that ATL cells display constitutive activation of the non-canonical Wnt pathway, and that elevated Wnt5a may be implicated in bone resorption.
Wnt5a secreted by ATL cells induces osteoclast differentiation.
In addition to ATL patient samples, we also found that Wnt5a was overexpressed in ATL cell lines ( Figure 5A and data not shown 
conditions. We seeded cells from the Wnt5a expressing, ATL cell line, MT1, into a transwell insert placed over C2C12 cells. As previously reported, an increase in the activity of the osteoblastic marker, alkaline phosphatase (ALP), was detected in C2C12 cells five days after stimulation with recombinant bone morphogenic proptein (rBMP-2) ( Figure 5B ) 23 . To demonstrate the specificity of these data, we established a DKK-1 Tet-inducible MT1 cell line, in which DKK-1 expression could be induced by doxycycline). In agreement with previously published studies, we found that DKK-1 secreted by MT1 cells was able to inhibit osteoblastic differentiation of C2C12 following rBMP-2 incubation, as shown by reduced levels of ALP activity ( Figure 5B ).
Real-time PCR confirmed that DKK-1 was induced in the MT1 cells ( Figure 5C ).
Since ATL patients have decreased expression of the majority of canonical Wnts, we tested whether Wnt3a, the key inducer of Wnt/canonical signaling, could disrupt the OPG/RANKL/RANK system in myoblasts cultured with ATL cells, since this system is the final mediator of osteoclastogenesis 24 . Addition of recombinant Wnt3a (rWnt3a) to C2C12 cells co-cultured with MT1 cells, increased the expression of the osteoblastic marker, OPG, but had no effect on RANK expression ( Figure 5D ). Consistent with the role of canonical signaling on osteoblastogenesis, rWnt3a mediated a slight downregulation of RANKL, a key activator of osteoclasts ( Figure 5D ).
We next aimed to demonstrate the role of non-canonical Wnt signaling, as mediated by the secretion of Wnt5a, in osteoclastogenesis in ATL cells. We took advantage of the fact that MT1 cells expressed high levels of Wnt5a ( Figure 5A ) and setup a transwell system with myoblasts in the presence or absence of Wnt5a antibodies ( Figure 5E ). As expected, blocking Wnt5a signaling with Wnt5a antibodies caused a reduction in RANK expression in the myoblast cells. Our results demonstrate a further, significant reduction in RANK receptor expression when Wnt5a secretion is blocked from MT1 cells in the presence of Wnt5a specific antibodies ( Figure 5F ). This is in The decrease in RANK expression observed in the presence of Wnt5a antibodies was not linked to non-specific toxicity as shown by unchanged levels of RANKL expression ( Figure 5F ). Finally, we tested early B cell factor -2 (EBF2) gene expression, a key regulator of RANK-RANKL signaling and osteoblast-dependent differentiation of osteoclasts 25 . We found that inhibition of Wnt5a secretion from ATL cells was sufficient to significantly elevate EBF2 expression in myoblasts ( Figure 5F ). Wnt5a mediation of EBF2 expression occurred only in the presence of rRANKL. Together our results suggest that in ATL cells, inhibition of canonical signaling and increases in noncanonical signaling through secretion of Wnt5a plays an important role in bone lytic lesions and may contribute to hypercalcemia.
DISCUSSION:
Hypercalcemia is a severe complication arising in over 80% of acute ATL patients and serves as a major prognostic factor for acute ATL disease outcome 26 .
Osteolytic bone lesions have been reported in acute ATL patients, along with elevated levels of RANKL, MIP-1α, PTHrP, and IL-6, and are believed to contribute to hypercalcemia 14;27-30 . Our results described herein reveal differential regulation of Wnt/β-catenin signaling between leukemic cells from ATL patients and HTLV-I cell lines.
We found readily detectable levels of 
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